MAZEHealthcare · BiotechnologyThe 12 Wall Street analysts covering Maze Therapeutics, Inc. hold a median 12-month price target of $55 — +86.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Maze Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (53): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MAZE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +86.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Aug 2026 | BTIG | Reiterates | Buy | $46 |
| 14 Apr 2026 | Truist Securities | Maintains | Buy | $68 → $64 |
| 14 Apr 2026 | Truist Securities | Maintains | Buy | — |
| 31 Mar 2026 | JP Morgan | Maintains | Overweight | — |
| 25 Mar 2026 | BTIG | Reiterates | Buy | — |
| 25 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Mar 2026 | Truist Securities | Initiates | Buy | — |
| 16 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 10 Mar 2026 | Mizuho | Initiates | Outperform | — |
| 9 Mar 2026 | BTIG | Reiterates | Buy | — |
| 4 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 16 Jan 2026 | BTIG | Maintains | Buy | — |
| 4 Dec 2025 | Wells Fargo | Initiates | Overweight | — |
| 3 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Nov 2025 | Wedbush | Maintains | Outperform | — |
| 29 Sept 2025 | JP Morgan | Maintains | Overweight | — |
| 18 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Sept 2025 | Guggenheim | Maintains | Buy | — |
| 12 Sept 2025 | BTIG | Maintains | Buy | — |
| 12 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MAZE appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 4% of US stocks
Cheaper than 5% of US stocks
Cheaper than 26% of US stocks
Cheaper than 83% of US stocks
Higher than 6% of US stocks
Higher than 30% of US stocks
Higher than 25% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Maze Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Maze Therapeutics announced that Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., have joined its Board of Directors, adding clinical and industry experience to the company's leadership.
Why it matters — New board appointments bring additional clinical and pharmaceutical expertise to Maze's leadership as the company advances its pipeline.
Maze Therapeutics reported second-quarter 2026 financial results, noting enrollment in the Phase 2 HORIZON trial of MZE829 is on track with data expected in late 2026 or early 2027. The company also initiated its Phase 2 CIPheR trial for MZE782 in PKU, expects topline data in 2027, and holds $495 million in cash supporting operations into 2029.
Why it matters — The update confirms progress across Maze's key clinical programs and a cash position expected to fund operations into 2029, providing visibility into near-term milestones.
The 12 Wall Street analysts covering Maze Therapeutics, Inc. have a median 12-month price target of $55, with estimates ranging from $46 to $110. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Maze Therapeutics, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Maze Therapeutics, Inc. 19 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Maze Therapeutics, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (53 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +86.9% from the last close, and Ticker Nerd's factor model ranks Maze Therapeutics, Inc. 19 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Maze Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MAZE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $46 to $110 over the next 12 months.
Maze Therapeutics, Inc. returned +122.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Maze Therapeutics Inc. is a clinical-stage biopharmaceutical company developing small molecule precision medicines for renal, cardiovascular, related metabolic diseases, and obesity.
The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Maze Therapeutics Announces Appointments to Its Board of Directors". Maze Therapeutics announced that Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., have joined its Board of Directors, adding clinical and industry experience to the company's leadership.
Maze Therapeutics Inc. is a clinical-stage biopharmaceutical company developing small molecule precision medicines for renal, cardiovascular, related metabolic diseases, and obesity. The company harnesses human genetics through its Compass platform to identify genetic variants in diseases and link them to biological pathways driving conditions in specific patient populations, a process called variant functionalization. Its lead program, MZE829, is an oral small molecule inhibitor of apolipoprotein L1 (APOL1) in phase II clinical trials for APOL1 kidney disease. MZE782, another oral small molecule inhibitor targeting the solute transporter SLC6A19, is in phase I clinical trials for chronic kidney disease and phenylketonuria. Maze Therapeutics Inc. also advances MZE001 for Pompe disease. Focused on novel precision medicine approaches, it addresses unmet needs in kidney and metabolic disorders. Founded in 2017 and headquartered in South San Francisco, California, Maze Therapeutics Inc. plays a key role in advancing genetically informed therapies in the biopharmaceutical sector.
CEO Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. · 141 employees · United States · https://www.mazetx.com